TC BioPharm Holdings Plc (TCBP)

[Danner79]

I like what's coming

- Released data from its Phase 1a/2b trial for TCB-002, OmnImmune in relapse/ refractory acute myeloid leukemia ("AML") 

-Plans to disclose additional phase 2/3 data in H1 2022.

-OmnImmunedemonstrated a “good safety and tolerability profile” TC Biopharm (TCBP) said, adding that there were no concerns on product-related safety, graft vs host disease, or cytokine release syndrome. 

-Owns approved GMP facilities and a decent IP portfolio with expiries beyond 2035.

-Clinical results generated so far have fetched the United States Federal Drug Administration ('FDA) orphan drug status for its method of treatment of AML. An application will be submitted to the FDA in 1H-2022 for conducting phase II/pivotal phase III clinical trials in the US in 2022 for the treatment of AML.